Fig. 1From: Midazolam increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via the miR-194-5p/HOOK3 axisCR-NSCLC cells were successfully inducted from the parental CS-NSCLC cells. The CS-NSCLC and CR-NSCLC cells were exposed to high-dose cisplatin treatment at differential time points, and A, B cell proliferation abilities and C, D cell viability were respectively examined by MTT assay and trypan blue staining assay. E–H The NSCLC cells were subjected to high-dose cisplatin treatment for 24 h, and the Annexin V-FITC or PI-positive apoptotic cells were examined by performing the FCM analysis. Individual experiment contained at least 3 repetitions, and *P < 0.05, **P < 0.01, and ***P < 0.001 was considered as statistical significanceBack to article page